Form 4: Veracyte CSO's Stock Withholding for Tax Obligations

Veracyte's Chief Scientific & Medical Officer, Phillip G. Febbo, reported the withholding of 2,955 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Phillip G. Febbo, Veracyte's Chief Scientific & Medical Officer, reported a change in beneficial ownership.
• On December 2, 2025, 2,955 shares of Veracyte common stock were withheld.
• This withholding was to satisfy tax obligations associated with the vesting of restricted stock units.
• The shares were valued at $46.16 per share for tax purposes.
• Following this transaction, Febbo directly beneficially owns 89,486 shares of Veracyte common stock.
• This transaction is not a sale but a mandatory tax-related event.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction itself is neutral as it's a tax event, but it stems from the positive event of RSU vesting, indicating compensation realization.

Positives

• The transaction indicates the vesting of restricted stock units, which is a form of compensation realized by the officer.

Future Outlook

na

Industry Context

na

Comparison to Industry Standards

• This is a standard Form 4 filing for tax withholding upon RSU vesting, a common practice across all public companies for executive compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine tax withholding, not a discretionary sale. It indicates executive compensation vesting.

Key Dates

Recommendation

This Form 4 details a routine tax-related transaction where shares were withheld to cover tax obligations upon the vesting of restricted stock units for a key executive. It does not represent a discretionary sale or purchase, and therefore, does not provide new fundamental information to alter an investment thesis. The vesting itself is a positive for the executive, but the transaction is neutral for stock valuation. A 'hold' recommendation is appropriate as this filing does not present a catalyst for significant price movement or a change in the company's underlying value.

Keywords

Veracyte, VCYT, Form 4, SEC Filing, Insider Transaction, Stock Withholding, Restricted Stock Units, RSU Vesting, Phillip G. Febbo, Chief Scientific & Medical Officer